Shows melatonin-based biohybrid spheroids accelerate intestinal repair in colitis, suggesting a transformative therapeutic approach.
Following injury, prostaglandin E 2 (PGE 2 ) drives intestinal epithelial repair by inducing revival stem cells (RSCs), which compensate for the loss of homeostatic Lgr5 + stem cells. Using intestinal organoid models, we demonstrate that melatonin potentiates the PGE 2 - or damage-induced RSC emergence rewiring cellular plasticity toward a fetal-like state and sustaining pro-regenerative YAP activity, thereby enhancing overall repair capacity. To translate this finding into a therapeutic application, we developed a biohybrid heterospheroid (Mel-HS) by combining melatonin-loaded poly(lactic-co-glycolic acid) microspheres with 3D-cultured mesenchymal stem cells (MSCs), which serve as a PGE 2 source. We confirmed that this biohybrid construct preserves the paracrine capacity of MSCs to secrete PGE 2 . Notably, Mel-HS demonstrates superior in vivo retention compared with naive 3D-MSCs, underscoring the cytoprotective effect of encapsulated melatonin in enhancing MSC viability. Furthermore, Mel-HS promoted robust RSC induction while simultaneously providing protection against inflammatory- and oxidative insults in vitro . In a colitis model, Mel-HS accelerated mucosal healing through the dual mechanisms—immunomodulation and enhanced RSC-driven repair—resulting in marked clinical improvement. Collectively, our findings highlight the therapeutic potential of enhancing endogenous regeneration with melatonin and MSCs, establishing a promising framework for next-generation biohybrid cell therapeutics in inflammatory bowel disease management.
No takes yet. Share an insight, caveat, or question.
Seo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: